资讯

Tempus AI, Inc. (NASDAQ:TEM) stock is trading higher on Friday after acquiring Paige, an AI company specializing in digital ...
Tempus AI shares were higher after the company said it agreed to buy Paige, an AI company focused on digital pathology, for $81.3 million. The stock was up 8.4% at $83.17 and has more than doubled so ...
Tempus AI has acquired the digital pathology developer Paige, including its FDA-cleared, artificial intelligence-powered ...
2025年8月19日,数据处理和外包服务公司Tempus AI(TEM)成交额为9.67亿美元,在当日美股中排第83名,成交额较昨日减少13.60%,当日成交量为1284.80万。 Tempus AI(TEM)于2025年8月19日跌6.85%,报73.08美元,该股过去5个交易日涨10.16%,整个8月涨29.14%,年初至今涨116.47%,过去52周涨26.85%。 *如果公司上市时间少于5 ...
Tempus AI was targeted by a short seller last week. Since then, the company has made several announcements that have helped quell doubts introduced by the short report. The company's stock jumped ...
Tempus AI (TEM) stock dropped 19% Tuesday, the day after the company released a Q4 earnings report that missed Street estimates and its 2025 financial forecast. Read more here.
Tempus AI achieves strong revenue growth and beats expectations, but ongoing losses and execution risks temper enthusiasm.
Tempus AI (NASDAQ:TEM) announced on Friday an acquisition of the AI company specializing in digital pathology, Paige, for $81 ...
It's called Recursion OS. Using 36 petabytes (36 million gigabytes) of biological and chemical data, Recursion OS can ...
Completing its initial public offering on June 14, Tempus AI stock closed at $40.25, and while it rose above this mark from time to time in the second half of 2024, the stock ended the year on a ...
Tempus AI stock rose on the strength of Q2 sales momentum The company saw an adjusted loss of $0.22 per share on revenue of $314.6 million in the second quarter. The average Wall Street analyst ...
Tempus AI stock rose on the strength of Q2 sales momentum The company saw an adjusted loss of $0.22 per share on revenue of $314.6 million in the second quarter.